Fruquintinib - Hutchison MediPharma

Drug Profile

Fruquintinib - Hutchison MediPharma

Alternative Names: HMPL-013

Latest Information Update: 07 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Hutchison MediPharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Colorectal cancer
  • Phase III Gastric cancer; Non-small cell lung cancer
  • Phase II Solid tumours

Most Recent Events

  • 04 Jun 2018 Additional adverse events and efficacy data from the phase III FRESCO trial in Colorectal cancer released by Hutchison MediPharma
  • 12 Mar 2018 Hutchison China MediTech plans to launch in China for Colorectal cancer (Second-line therapy or greater) in 2018
  • 13 Feb 2018 Hutchison China MediTech announces intention to submit second NDA for Non-small cell lung cancer to China FDA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top